Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023. This session is open to all existing and prospective shareholders. Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [email protected]

Share on:

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:
Nuformix plc

Latest Company News

Nuformix adds new preclinical support for NXP002

August 21, 2026

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions.

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

August 21, 2026

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners.

Nuformix reports positive NXP002 inhalation study results

August 19, 2026

Nuformix has reported positive inhaled NXP002 preclinical data, supporting pulmonary exposure, target engagement and further development planning.

Pulmonary fibrosis care needs support a long-term treatment market

August 10, 2026

Pulmonary fibrosis creates long-term demand for treatments, respiratory equipment and patient-support services as care needs increase over time.

Nuformix strengthens financial position and advances NXP002 programme

May 28, 2026

Nuformix reported a reduced interim loss and a significantly improved cash position for the six months ended 31 March 2026, supported by successful fundraisings and progress with NXP002, including FDA Orphan Drug Designation in IPF.

Dr Dan Gooding on Nuformix’s NXP002 opportunity in idiopathic pulmonary fibrosis

April 1, 2026

Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions.

Nuformix hosting online Q&A session on 13 June 2023

We’ll keep you in the loop!

Latest Company News

Search

Follow us on Social Media: